Pablo Jiménez· @PaulJiL · X·· 1 天前评分45
正文 · 原文
#ESMO26 #HNSCC
Nice presentation from Dr Even about the systemic approach of HPV+ HNSCC
My take: Is time to end with antiEGFR agents in HPV+ HNSCC? or shall we keep it as a last resource in latter lines
None of the major guidelines (ASCO, ESMO and NCCN) do make any clear recommendation against/disadvice
@OncoAlert @myESMO @brunolarvol
@DavidSherMD
54 浏览 · 3 赞 · 3 转发 · 0 回复
会议摘要
NCT06295731NCT06295731按 - **标题 / Title：** INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC 对上
- **标题 / Title：** INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
https://esmocongress.esmo.org来源：Pablo Jiménez · x.com